After SNY's PARP inhibitor failure, I see that AZN's compound Olaparib/AZD2281 (developed by KuDOS), is now in the Discontinued Projects section in gBRCA breast:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.